Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-049448

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Christopher Haqq
Officer — EVP, R&D & Chief Scientific Of
Period of report
Aug 15, 2017
Accepted (ET)
Aug 17, 2017 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Aug 15, 2017M829$0.00A362,909D
Common StockAug 15, 2017S7,604$14.75D355,305D
Common StockF3holding———17,312ISee footnote
Common StockF4holding———2,688ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitsF5,F6,F7—Aug 15, 2017M829D——Common Stock8291,382D

Explanation of responses